A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy

Clinics

Volumn 67, Issue 4, 2012, Pages 363-373

  Sui, Weiguo ^a   Li, Liping ^a,b   Che, Wenti ^a   Zuo, Guimai ^a   Chen, Jiejing ^a   Li, Wuxian ^c   Dai, Yong ^a,d  

^a Central Laboratory   (China)

^b GUANGXI NORMAL UNIVERSITY   (China)

^c CHONGQING MEDICAL UNIVERSITY   (China)

^d SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

Biomarkers; Immunoglobulin A nephropathy; Metabonomics; Orthogonal partial least squares discriminant analysis; Proton nuclear magnetic resonance spectroscopy

Indexed keywords

BIOLOGICAL MARKER; PROTON;

ADOLESCENT; ADULT; ARTICLE; BIOPSY; CASE CONTROL STUDY; DISCRIMINANT ANALYSIS; FEMALE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY; MALE; METABOLISM; METABOLOMICS; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; DISCRIMINANT ANALYSIS; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; KIDNEY; LEAST-SQUARES ANALYSIS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; PROTONS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84860212240     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(04)10     Document Type: Article

References (45)

1. Damico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64(245):709-27.
2. Bartosik LP, Lajoie G, Sugar L, Cattran DCPredicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38(4):728-35. http://dx.doi.org/10.1053/ajkd.2001.27689.
3. Coppo R, Damico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18(5):503-12.
4. Yamamoto R, Imai E. A novel classification for IgA nephropathy. Kidney International. 2009;76(3):477-80 http://dx.doi.org/10.1038/ki.2009.206.
5. Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2011;29: [Epub ahead of print].
6. Laville M, Alamartine E. Treatment options for IgA nephropathy in adults: a proposal for evidence-based strategy. Nephrol Dial Transplant. 2004;19(8):1947-51. http://dx.doi.org/10.1093/ndt/gfh309.
7. Carvalho E, do Sameiro Faria M, Nunes JP, Sampaio S, Valbuena C. Renal diseases: a 27-year renal biopsy study. J Nephrol. 2006;19(4):500-7.
8. Weiguo Sui, Yong Dai, Yue Zhang, Jiejing Chen, Huaying Liu, He Huang, et al. Proteomic profiling of immunoglobulin A nephropathy in serum using magnetic bead based sample fractionation and matrix- assisted laser desorption/ionization-time of flight mass spectrometry. Saudi Med J. 2010;31(12):2-3.
9. Peters HP, van den Brand JA, Wetzels JF. Urinary excretion of low- molecular-weight proteins as prognostic markers in IgA nephropathy. Neth J Med. 2009;67(2):54-61.
10. Lindon JC, Nicholson JK. Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery. Trends Anal. Chem. 2008;27(3):194-204. http://dx.doi.org/10.1016/j.trac.2007.08.009.
11. Coen M, Holmes E, Lindon JC, Nicholson JK. NMR-based metabolic profiling and metabonomic approaches to problems in molecular toxicology. Chem Res Toxicol. 2008;21(1):9-27. http://dx.doi.org/10.1021/tx700335d.
12. Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, et al. Human metabolic phenotype diversity and its association with diet and blood pressure. Nature. 2008;453(7193):396-400. http://dx.doi.org/10.1038/nature06882.
13. Kaddurah-Daouk R, Krishnan KR. Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology. 2009;34(1):173-86. http://dx.doi.org/10.1038/npp.2008.174.
14. Ala-Korpela M. Potential role of body fluid 1H NMR metabonomics as a prognostic and diagnostic tool. Expert Rev Mol Diagn. 2007;7(6):761-73. http://dx.doi.org/10.1586/14737159.7.6.761.
15. Pradat PF, Dib M. Biomarkers in amyotrophic lateral sclerosis: facts and future horizons. Mol Diagn Ther. 2009;13(2):115-25.
16. Serkova N, Klawitter J, Niemann CU. Organ-specific response to inhibition of mitochondrial metabolism by cyclosporine in the rat. Transpl Int. 2003;16(10):748-55. http://dx.doi.org/10.1111/j.1432-2277.2003.tb00235.x.
17. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med. 2002;8(12):1439-44. http://dx.doi.org/10.1038/nm1202-802.
18. Beckwith-Hall BM, Holmes E, Lindon JC, Gounarides J, Vickers A, Shapiro M, et al. NMR-based metabonomic studies on the biochemical effects of commonly used drug carrier vehicles in the rat. Chem Res Toxicol. 2002;15(9):1136-41. http://dx.doi.org/10.1021/tx020020+.
19. Ludwig C, Ward DG, Martin A, Viant MR, Ismail T, Johnson PJ, et al. Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magn Reson Chem. 2009;47(Suppl 1):S68-73. http://dx.doi.org/10.1002/mrc.2519.
20. Tiziani S, Lopes V, Gunther UL. Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia. 2009;11(3):269-76.
21. Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009;100(4):782-5. http://dx.doi.org/10.1111/j.1349-7006.2009.01086.x.
22. Maher AD, Crockford D, Toft H, Malmodin D, Faber JH, McCarthy MI, et al. Optimization of human plasma 1H NMR spectroscopic data processing for high-throughput metabolic phenotyping studies and detection of insulin resistance related to type 2 diabetes. Anal Chem 2008;80(19):7354-62. http://dx.doi.org/10.1021/ac801053g.
23. Quinones MP, Kaddurah-Daouk R. Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis. 2009;35(2):165-76. http://dx.doi.org/10.1016/j.nbd.2009.02.019.
24. Jung JY, Lee HS, Kang DG, Kim NS, Cha MH, Bang OS, et al. 1H-NMR- Based Metabolomics Study of Cerebral Infarction. Stroke. 2011;42(5): 1282-8. http://dx.doi.org/10.1161/STROKEAHA.110.598789.
25. Kang SM, Park JC, Shin MJ, Lee H, Oh J, Ryu do H, et al. (1)H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clin Biochem. 2011;44(4):293-9. http://dx.doi.org/10.1016/j.clinbiochem.2010.11.010.
26. Larsen FH, van den Berg F, Engelsen SB. An exploratory chemometric study of 1H NMR spectra of table wines. J Chemometr. 2006;20(4):198-208. http://dx.doi.org/10.1002/cem.991.
27. Wiklund S, Johansson E, Sjostrom L, Mellerowicz EJ, Edlund U, Shockcor JP, et al. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anal Chem.2008;80(1):115-22. http://dx.doi.org/10.1021/ac0713510.
28. Ni Y, Su M, Lin J, Wang X, Qiu Y, Zhao A, et al. Metabolic profiling reveals disorder of amino acid metabolism in four brain regions from a rat model of chronic unpredictable mild stress. FEBS Lett. 2008;582(17):2627-36. http://dx.doi.org/10.1016/j.febslet.2008.06.040.
29. Aarøe J, Lindahl T, Dumeaux V, Saebø S, Tobin D, Hagen N, et al. Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res. 2010;12(1):R7. http://dx.doi.org/10.1186/bcr2472.
30. Wishart DS, Lewis MJ, Morrissey JA, Flegel MD, Jeroncic K, Xiong Y, et al. The human cerebrospinal fluid metabolome. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;871(2):164-73.
31. 1H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure. Clinical Biochemistry. 2011;44(4):293-9. http://dx.doi.org/10.1016/j.clinbiochem.2010.11.010.
32. Grove H, Jørgensen BM, Jessen F, Søndergaard I, Jacobsen S, Hollung K, et al. Combination of statistical approaches for analysis of 2-DE data gives complementary results. J Proteome Res. 2008;7(12):5119-24. http://dx.doi.org/10.1021/pr800424c.
33. Nakamaki S, Satoh H, Kudoh A, Hayashi Y, Hirai H, Watanabe T. Adiponectin reduces proteinuria in streptozotocin-induced diabetic Wistar rats. Exp Biol Med (Maywood). 2011;236(5):614-20. http://dx.doi.org/10.1258/ebm.2011.010218.
34. Rifai A, Dworkin LD. IgA nephropathy: markers of progression and clues to pathogenesis. Kidney Int. 2008;73(12):1338-40. http://dx.doi.org/10.1038/ki.2008.158.
35. Suzuki H, Moldoveanu Z, Hall S, Brown R, Vu HL, Novak L, et al. IgA1 secreting cell lines from patients with IgA nephropathy produce aberrantly glycosylated IgA1. J Clin Invest. 2008;118(2):629-39.
36. Oberholzer J, Testa G, Sankary H, et al. Kidney transplantation at the University of Illinois at Chicago from 1988-2004. Clin Transpl. 2004;143-9.
37. Graham GD, Blamire AM, Howseman AM, Rothman DL, Fayad, PB. Brass LM, et al. Proton magnetic resonance spectroscopy of cerebral lactate and other metabolites in stroke patients. Stroke. 1992;23(3):333-40. http://dx.doi.org/10.1161/01.STR.23.3.333.
38. Waters NJ, Waterfield CJ, Farrant RD, Holmes E, Nicholson JK. Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato- and nephrotoxicity. Chem ResToxicol. 2005;18(4):639-54.
39. Nicholson JK, Lindon JC, Holmes E. Metabonomics: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11):1181-9. http://dx.doi.org/10.1080/004982599238047.
40. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers. 2004;9(1):1-31. http://dx.doi.org/10.1080/13547500410001668379.
41. Kumar A, Bala L, Kalita J, Misra UK, Singh RL, Khetrapal CL, et al. Metabolomic analysis of serum by (1) H NMR spectroscopy in amyotrophic lateral sclerosis. Clin Chim Acta. 2010;411(7-8):563-7. http://dx.doi.org/10.1016/j.cca.2010.01.016.
42. Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM. Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm. 2006;3:496-506. http://dx.doi.org/10.1021/mp060067e.
43. Lovejoy TI, Revenson TA, France CR. Reviewing manuscripts for peerreview journals: a primer for novice and seasoned reviewers. Ann Behav Med. 2011;42(1):1-13. http://dx.doi.org/10.1007/s12160-011-9269-x.
44. Garmel GM. Reviewing manuscripts for biomedical journals. Perm J. 2010;14(1):32-40.
45. Lee SM, Rao VM, Franklin WA, Schiffer MS, Aronson AJ, Spargo BH, et al. IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982;13(4):314-22. http://dx.doi.org/10.1016/S0046-8177(82)80221-9.